JBIO (Aerovate Therapeutics) Short-Term Debt to Capital

Aerovate Therapeutics Inc (JBIO) is a biopharmaceutical innovator investing in the development of unique inhalation therapies to combat pulmonary hypertension. The company's price chart is available due to partnerships with pulmonology centers as part of joint drug trials. The current metric stands at 0.00, while the business lacks a stable cash flow and relies solely on remaining capital during its restructuring period.

The short-term debt-to-equity ratio measures the proportion of liabilities maturing within one year relative to shareholders' equity. By analyzing the historical relationship between short-term loans and equity, an investor assesses the risk of immediate insolvency. This metric is sensitive to liquidity levels, which is critical for Aerovate Therapeutics Inc (JBIO). In the absence of commercial revenue and amidst program restructuring, reliance on short-term borrowing directly determines the business's viability.